^
    Back
    Association details:
    Biomarker:MET overexpression
    Cancer:Melanoma
    Drug Class:BRAF inhibitor +
    MEK inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    SSO 2020
    Title:

    P236: Mechanisms of Resistance in BRAF Mutated Melanoma to BRAF-MEK Inhibition Revealed by Single Cell RNA Sequencing

    Excerpt:
    We created a scRNA (single cell RNA) atlas of 286,003 cells over 19 melanoma tumor specimens from 16 patients...we generated tumor-derived cell lines from two BRAFmut samples who were not on BRAF-MEK inhibitor therapy, followed by creation of resistant cell lines after in-vitro BRAF-MEK inhibitor treatment….In BRAF-MEK treatment resistant lines, MET and TRIB3were highly expressed...